The relationship between the results of in silico and in vivo studies of hypoglycemic, hypolypidemic, hepatoprotective properties of a new 1,4-dihydropyridine derivative

Objective: determination of the relationship between the results of in silico and in vivo studies of hypoglycemic, hypolipidemic, hepatoprotective properties of a new 1,4-dihydropyridine derivative coded AZ-383. Material and methods. Virtual bioscreening of compound AZ-383 was carried out using Swiss Target Prediction programs. The identified biotargets were promising for the pharmacocorrection of a complex of metabolic disorders, which was confirmed in an experiment conducted on male Wistar rats. In vivo, the levels of glucose, total cholesterol, triglycerides, ALT, AST, and total bilirubin in the blood were studied; the microarchitecture of the rat liver was assessed after pharmacocorrection of simulated metabolic disorders with the compound AZ-383.